RELMADA THERAPEUT.DL-001
Relmada Therapeutics, Inc. operates as a clinical-stage biotechnology company in the United States. The company focuses on the development of NDV-01, a controlled-release intravesical formulation of gemcitabine and docetaxel, which is in Phase 2 clinical trial for patients with aggressive forms of non-muscle invasive bladder cancer; and sepranolone, a neurosteroid epimer of allopregnanolone, whic… Read more
Market Cap & Net Worth: RELMADA THERAPEUT.DL-001 (4E2)
RELMADA THERAPEUT.DL-001 (F:4E2) has a market capitalization of $49.12K (€47.85K) as of March 19, 2026. Listed on the F stock exchange, this Germany-based company holds position #12020 globally and #1283 in its home market, demonstrating a -13.22% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying RELMADA THERAPEUT.DL-001's stock price €5.25 by its total outstanding shares 9114 (9.11K).
RELMADA THERAPEUT.DL-001 Market Cap History: 2023 to 2026
RELMADA THERAPEUT.DL-001's market capitalization history from 2023 to 2026. Data shows growth from $31.62K to $49.12K (11.31% CAGR).
RELMADA THERAPEUT.DL-001 Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how RELMADA THERAPEUT.DL-001's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
No P/S ratio data available
Latest Price to Earnings (P/E) Ratio
No P/E ratio data available
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| No financial ratio data available | |||||
Competitor Companies of 4E2 by Market Capitalization
Companies near RELMADA THERAPEUT.DL-001 in the global market cap rankings as of March 19, 2026.
Key companies related to RELMADA THERAPEUT.DL-001 by market ranking:
- Shanghai Shenda Co Ltd (SHG:600626): Ranked #12011 globally with a market cap of $353.38 Million USD ( CN¥2.59 Billion CNY).
- Sichuan Kexin Mechanic Electric (SHE:300092): Ranked #12012 globally with a market cap of $353.13 Million USD ( CN¥2.59 Billion CNY).
- Shenzhen Genvict Technologies Co Ltd (SHE:002869): Ranked #12021 globally with a market cap of $352.50 Million USD ( CN¥2.59 Billion CNY).
- Chuzhou Duoli Automotive Technology Co. Ltd. A (SHE:001311): Ranked #12022 globally with a market cap of $352.50 Million USD ( CN¥2.59 Billion CNY).
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #12011 | Shanghai Shenda Co Ltd | SHG:600626 | $353.38 Million | CN¥4.49 |
| #12012 | Sichuan Kexin Mechanic Electric | SHE:300092 | $353.13 Million | CN¥16.44 |
| #12021 | Shenzhen Genvict Technologies Co Ltd | SHE:002869 | $352.50 Million | CN¥23.17 |
| #12022 | Chuzhou Duoli Automotive Technology Co. Ltd. A | SHE:001311 | $352.50 Million | CN¥32.58 |
RELMADA THERAPEUT.DL-001 Historical Marketcap From 2023 to 2026
Between 2023 and today, RELMADA THERAPEUT.DL-001's market cap moved from $31.62K to $ 49.12K, with a yearly change of 11.31%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | €49.12K | +44.23% |
| 2025 | €34.05K | +911.11% |
| 2024 | €3.37K | -89.35% |
| 2023 | €31.62K | -- |
End of Day Market Cap According to Different Sources
On Mar 18th, 2026 the market cap of RELMADA THERAPEUT.DL-001 was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $49.12K USD |
| MoneyControl | $49.12K USD |
| MarketWatch | $49.12K USD |
| marketcap.company | $49.12K USD |
| Reuters | $49.12K USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.